London
· Delayed Price · Currency is GBP · Price in EUR Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of GBP 82.92 million. The enterprise value is 37.48 million.
| Market Cap | 82.92M |
| Enterprise Value | 37.48M |
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +58.85% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 39.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.11 |
| PB Ratio | 0.79 |
| P/TBV Ratio | 0.80 |
| P/FCF Ratio | 5.09 |
| P/OCF Ratio | 4.52 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.28 |
| EV / Sales | 0.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.30 |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.73 |
| Quick Ratio | 1.00 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | n/a |
| Debt / FCF | 4.33 |
| Interest Coverage | -7.99 |
Financial Efficiency
Return on equity (ROE) is -34.08% and return on invested capital (ROIC) is -19.21%.
| Return on Equity (ROE) | -34.08% |
| Return on Assets (ROA) | -10.37% |
| Return on Invested Capital (ROIC) | -19.21% |
| Return on Capital Employed (ROCE) | -27.41% |
| Revenue Per Employee | 179,512 |
| Profits Per Employee | -134,080 |
| Employee Count | 222 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.37% in the last 52 weeks. The beta is 3.38, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 3.38 |
| 52-Week Price Change | -44.37% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 1.69 |
| Relative Strength Index (RSI) | 55.76 |
| Average Volume (20 Days) | 1,649 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cellectis had revenue of GBP 39.31 million and -29.36 million in losses. Loss per share was -0.33.
| Revenue | 39.31M |
| Gross Profit | 39.31M |
| Operating Income | -47.57M |
| Pretax Income | -29.36M |
| Net Income | -29.36M |
| EBITDA | -38.54M |
| EBIT | -47.57M |
| Loss Per Share | -0.33 |
Balance Sheet
The company has 114.42 million in cash and 70.51 million in debt, giving a net cash position of 43.92 million.
| Cash & Cash Equivalents | 114.42M |
| Total Debt | 70.51M |
| Net Cash | 43.92M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 104.67M |
| Book Value Per Share | 1.45 |
| Working Capital | 96.49M |
Cash Flow
In the last 12 months, operating cash flow was 18.36 million and capital expenditures -2.06 million, giving a free cash flow of 16.30 million.
| Operating Cash Flow | 18.36M |
| Capital Expenditures | -2.06M |
| Free Cash Flow | 16.30M |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -121.00% and -74.69%.
| Gross Margin | 100.00% |
| Operating Margin | -121.00% |
| Pretax Margin | -74.69% |
| Profit Margin | -74.69% |
| EBITDA Margin | -98.04% |
| EBIT Margin | -121.00% |
| FCF Margin | 41.46% |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.85% |
| Shareholder Yield | -58.85% |
| Earnings Yield | -35.41% |
| FCF Yield | 19.66% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -0.73. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.73 |
| Piotroski F-Score | n/a |